Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

Benzer Materyaller

• Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
  Yazar:: Fava, Carmen, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid Leukemia
  Yazar:: Quintás-Cardama, Alfonso, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
  Yazar:: Garg, Ravin J., ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients with Chronic Phase Chronic Myeloid Leukemia After Failure to Frontline Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?
  Yazar:: Cortes, Jorge, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
  Yazar:: Jabbour, Elias, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)